Serum Levels of Sirtuin-1 in Patients with Lung Cancer and its Association with Karnofsky Performance Status Sirtuin-1 in lung cancer

Main Article Content

Hassan Ghobadi

Keywords

Lung cancer, Sirtuin-1, Quality of life, Karnofsky performance status.

Abstract

Background: Lung cancer is a major cause of cancer-related deaths worldwide. There are conflicting results regarding the role of sirtuin-1 in cancer. This study aimed to evaluate the serum sirtuin-1 levels in patients with lung cancer and its relationship with the quality of life based on Karnofsky performance statue scale (KPS).


Methods: Serum sirtuin-1 levels were measured in 30 male patients with lung cancer and 50 healthy men. The two groups were matched for age. The difference between the serum levels of sirtuin-1 between the two groups and its relationship with KPS and other clinical parameters were evaluated. Data were analyzed by independent t-test and Pearson correlation, and P < 0.05 was considered as significant.


Results: Sirtuin-1 levels were significantly lower in the patients in comparison with healthy subjects (P < 0.001). There was also a significant relationship between the serum level of sirtuin-1 with KPS (P < 0.001, r = 0.634), arterial oxygen saturation (P < 0.01, r = 0.470), and smoking history (P < 0.01, r = -0.330). In addition, the serum sirtuin-1 levels were significantly lower in adenocarcinoma than that in squamous cell carcinoma or small cell lung cancer (p < 0.001 and P < 0.05, respectively).


Conclusion: The serum levels of sirtuin-1 were lower in patients with lung cancer. In addition, there was a significant correlation between serum levels of sirtuin-1 and KPS, O2 saturation, and smoking history. Further serological and histological studies seem to be necessary due to the existence of conflicting reports regarding sirtuin-1.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 31 |

References

1. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet. 2013;382(9893):709-19.
2. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907.
3. Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician. 2015;91(4):250-6.
4. Barta JA, Powell CA, Wisnivesky JP. Global Epidemiology of Lung Cancer. Ann Glob Health. 2019;85(1).
5. Vardanjani HM, Zeinali M, Radmerikhi S, Hadipour M. Lung cancer prevalence in Iran by histologic subtypes. Advanced biomedical research. 2017;6.
6. Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9(2):154-62.
7. Chalkiadaki A, Guarente L. The multifaceted functions of sirtuins in cancer. Nat Rev Cancer. 2015;15(10):608-24.
8. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science. 2004;305(5682):390-2.
9. Fang Y, Nicholl MB. Sirtuin 1 in malignant transformation: friend or foe? Cancer Lett. 2011;306(1):10-4.
10. Jang SH, Min KW, Paik SS, Jang KS. Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma. J Clin Pathol. 2012;65(8):735-9.
11. Huffman DM, Grizzle WE, Bamman MM, Kim JS, Eltoum IA, Elgavish A, et al. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 2007;67(14):6612-8.
12. Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 2005;19(10):1751-9.
13. Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res. 2007;299(2):103-6.
14. Wang RH, Sengupta K, Li C, Kim HS, Cao L, Xiao C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008;14(4):312-23.
15. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69(5):1702-5.
16. Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O, et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010;1:3.
17. Jang KY, Hwang SH, Kwon KS, Kim KR, Choi HN, Lee NR, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32(10):1523-31.
18. Jang KY, Kim KS, Hwang SH, Kwon KS, Kim KR, Park HS, et al. Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 2009;41(4):366-71.
19. Latifkar A, Ling L, Hingorani A, Johansen E, Clement A, Zhang X, et al. Loss of Sirtuin 1 Alters the Secretome of Breast Cancer Cells by Impairing Lysosomal Integrity. Dev Cell. 2019;49(3):393-408.e7.
20. Sun L, Li H, Chen J, Dehennaut V, Zhao Y, Yang Y, et al. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis. J Natl Cancer Inst. 2013;105(12):887-98.
21. Sun L, Li H, Chen J, Iwasaki Y, Kubota T, Matsuoka M, et al. PIASy mediates hypoxia-induced SIRT1 transcriptional repression and epithelial-to-mesenchymal transition in ovarian cancer cells. J Cell Sci. 2013;126(Pt 17):3939-47.
22. Aslani MR, Matin S, Nemati A, Mesgari Abbasi M, Ghorbani S, Ghobadi H. Effects of conjugated linoleic acid supplementation on serum levels of interleukin-6 and sirtuin 1 in COPD patients. Avicenna Journal of Phytomedicine. 2019.
23. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. Embo j. 2002;21(23):6539-48.
24. Gao Z, Ye J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem Biophys Res Commun. 2008;376(4):793-6.
25. Simic P, Williams EO, Bell EL, Gong JJ, Bonkowski M, Guarente L. SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep. 2013;3(4):1175-86.
26. Gharabaghi MA. Diagnostic investigation of BIRC 6 and SIRT 1 protein expression level as potential prognostic biomarkers in patients with non‐small cell lung cancer. The clinical respiratory journal. 2018;12(2):633-8.
27. Wang J, Wang C. Prognostic and Predictive Role of Sirtuin1 Expression in Lung Adenocarcinoma. Clin Lab. 2016;62(10):1989-94.
28. Grbesa I, Pajares MJ, Martínez-Terroba E, Agorreta J, Mikecin A-M, Larráyoz M, et al. Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients. PLoS One. 2015;10(4):e0124670.
29. Yanagisawa S, Papaioannou AI, Papaporfyriou A, Baker JR, Vuppusetty C, Loukides S, et al. Decreased Serum Sirtuin-1 in COPD. Chest. 2017;152(2):343-52.